Trends in Sodium–Glucose Cotransporter 2 Inhibitor and Glucagon‑Like Peptide‑1 Receptor Agonist Prescription Rates Among Patients With Type 2 Diabetes: An Epic Cosmos Real-World Data Analysis, 2014-2024

AACE Endocrinology and Diabetes · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles